Thesis
momentum-code follows one of the oldest and most empirically supported edges in equity markets: buy yesterday's winners. The strategy scans a 24-symbol universe of large-cap U.S. names — spanning tech, financials, healthcare, consumer staples, energy, and industrials — and rotates into the top positive movers, capping exposure per position to limit concentration risk.
The universe is deliberately blue-chip: AAPL, NVDA, MSFT, JPM, XOM, and peers. That keeps liquidity risk near zero and avoids the noise that plagues small-cap momentum plays, but it also means the strategy competes in the most efficient corner of the market.
Backtest Performance
Over 451 trading days, momentum-code compounded to a 19.76% total return (10.6% CAGR), ending at $11,976 from a $10,000 base. Five total trades and $5 in fees make this an extremely low-churn approach despite a reported turnover of 92.74% — that figure likely reflects the sizing rotation rather than frequent round-trips.
The Sharpe ratio of 0.65 is modest. A 20.48% maximum drawdown against a sub-1 Sharpe is the headline tension: the strategy earns roughly two-thirds of a unit of return per unit of risk, which is acceptable but not exceptional for a rules-based momentum system.
Win rate is reported as 0%, which warrants a note: with only five trades in the backtest, this metric is statistically meaningless and should be disregarded.
Walk-Forward Validation
The four-fold walk-forward picture is more nuanced than the headline pass/fail suggests:
| Fold | Period | Return | Sharpe | Max DD |
|---|---|---|---|---|
| 1 | Aug 2024 – Jan 2025 | +15.38% | 2.47 | 6.12% |
| 2 | Jan 2025 – Jul 2025 | +3.27% | 0.46 | 16.55% |
| 3 | Jul 2025 – Dec 2025 | +12.18% | 2.31 | 5.21% |
| 4 | Dec 2025 – May 2026 | +13.71% | 1.93 | 6.32% |
All four folds are positive — a meaningful signal. Three of the four posted Sharpe ratios above 1.9. Fold 2 is the outlier: a 16.55% drawdown and near-zero risk-adjusted return coinciding with the volatile early-2025 period, when the momentum factor broadly underperformed during rapid sector rotations.
Despite those fold results, the strategy did not pass validation. The Probabilistic Sharpe Ratio (PSR) of 0.811 and, critically, the Deflated Sharpe Ratio (DSR) of 0.338 are the blockers. With six trials in the search space, the DSR applies a multiple-testing correction that substantially discounts the observed Sharpe. In plain terms: the strategy may have gotten lucky in parameter selection, and the edge hasn't yet been proven robust enough to survive that discount.
Recent Activity
The strategy has been fully deployed since late May, entering XOM (×13), NVDA (×8), BAC (×38), HON (×8), and MSFT (×4) across two sessions on May 31 and June 1. Since then, six consecutive daily runs have executed zero trades — all candidates were rejected. Portfolio value has drifted from $9,573 on June 19 down to $9,431 on June 25, reflecting mark-to-market moves on existing positions rather than any new activity.
The rejection pattern is consistent with a disciplined signal filter: the strategy only buys confirmed positive movers and has found no qualifying setups in the current environment.
Risks to Watch
- DSR overhang: Until more out-of-sample data accumulates and the DSR clears its threshold, treat this as a paper-trading candidate, not a capital-allocation one.
- Regime sensitivity: Fold 2 demonstrates that sharp market reversals can hit momentum hard. The current macro environment — with rate uncertainty and sector rotation risk — rhymes with that period.
- Trade count: Five backtest trades is an extremely thin sample. Statistical conclusions about the edge are premature.
Bottom Line
momentum-code has the right bones: a grounded thesis, all-positive folds, and clean execution infrastructure. The validation flag isn't a verdict against the strategy — it's a prompt for more data. Another quarter of live paper-trading performance, particularly through a volatile episode, would go a long way toward resolving the DSR concern.